Literature DB >> 24269566

Etrolizumab: anti-β7-a novel therapy for ulcerative colitis.

Kirk K Lin1, Uma Mahadevan1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24269566     DOI： 10.1053/j.gastro.2013.11.013

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  3 in total

Review 1.  A State-of-the-Art Review of New and Emerging Therapies for the Treatment of IBD.

Authors:  Kenechukwu O Chudy-Onwugaje; Kaci E Christian; Francis A Farraye; Raymond K Cross
Journal:  Inflamm Bowel Dis       Date:  2019-04-11       Impact factor: 5.325

Review 2.  Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease.

Authors:  Ioannis Mitroulis; Vasileia I Alexaki; Ioannis Kourtzelis; Athanassios Ziogas; George Hajishengallis; Triantafyllos Chavakis
Journal:  Pharmacol Ther       Date:  2014-11-14       Impact factor: 12.310

Review 3.  The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes.

Authors:  Gionata Fiorino; Daniela Gilardi; Silvio Danese
Journal:  Therap Adv Gastroenterol       Date:  2016-05-19       Impact factor: 4.409
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.